Doylestown, Pa. (PRWEB) November 29, 2017
Bioclinica®, a world-leading provider of specialty clinical trial services, has appointed William Hogan as the company’s Executive Vice President and Chief Financial Officer. Former CFO David Peters is stepping down to pursue other career opportunities.
William Hogan joins Bioclinica from Multi Packaging Solutions (“MPS”), a multinational, $2 billion manufacturer of specialty packaging for the pharmaceutical and consumer products industries. He was CFO for 12 years and served on the leadership team that managed MPS’s global expansion through several transactions including the sale of the business. His experience meeting the needs of the world’s top pharmaceutical companies will provide great insight into serving Bioclinica customers.
Prior to MPS, Hogan held CFO roles in multinational product and services-based businesses, both public reporting companies and private equity owned organizations, as well as 12 years with Deloitte. He is a certified public accountant and has extensive experience in the strategic, financial and operational management of multinational organizations. He brings a strong track record of increasing shareholder value and meeting the challenges created by evolving companies and rapidly changing economic and competitive environments.
David Herron, who will assume the role of Chief Executive of Bioclinica in January, said, “I would like to welcome Bill Hogan to Bioclinica, and, on behalf of the Board, we look forward to working with him to grow the business. Bill brings with him significant CFO experience from a variety of different businesses and his experience with over 19 acquisitions transactions will be an asset to Bioclinica.”
Hogan said, “Bioclinica is a world-leading provider of specialty clinical trial services and has ambitious plans for the future. I am delighted to have joined Bioclinica and am excited to be working alongside the Bioclinica management team to support the growth strategy. Bioclinica has a great team in place with an outstanding reputation and I look forward to our future success.”
Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company’s cloud-based offerings include medical imaging; cardiac safety; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site payments and forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development. The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.